StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Iomeprol

HCID 3731
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
78649-41-9
Standard-SMILES
CN(C(=O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
Summenformel
C17H22I3N3O8
Durchschnittliche Molmasse
777,1 g/mol
Monoisotopische Masse
776,8541

Überblick

Iomeprol is a benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position. It has a role as a xenobiotic, a radioopaque medium and an environmental contaminant. It is an organoiodine compound and a benzenedicarboxamide.

Namen und Bezeichner

Bevorzugter Name
Iomeprol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide
Englischer Name
IOMEPROL
Summenformel
C17H22I3N3O8
Molmasse
777.09

Namen und Synonyme

iomeprol78649-41-9IomeronIomeprolumIomeproloDTXSID1049061Iomeron 300IOMERVUE-7337N,N'-Bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(N-methylglycolamido)isophthalamide17E17JBP8LDTXCID2028987
Weitere Namen anzeigen
Iomepol.Iomeron 350ImeronImeron 300Iomeprogr.Iomeprol materialIOMEPROL USP/EP/BPC14348000 Iomeprol
E7337CHEBI:31710N,N'-bis(2,3-dihydroxypropyl)-5-[glycoloyl(methyl)amino]-2,4,6-triiodoisophthalamide1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)methylamino)-2,4,6-triiodo-Iomeprol InjectionN,N'-bis(2,3-dihydroxypropyl)-5-(glycoloyl(methyl)amino)-2,4,6-triiodoisophthalamideRefChem:57671V08AB10

Datenbank-Bezeichner

CAS
78649-41-9
PubChem CID
3731
DTXSID
DTXSID1049061
ChEMBL
CHEMBL2107214
ChEBI
CHEBI:31710
UNII
17E17JBP8L
Nikkaji
J277.762B

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-2,3
Polarare Oberfläche (TPSA)
180 Ų
H-Brücken-Donoren
7
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
10
Schwere Atome
31
Formalladung
0
Komplexität
591

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point285-291
Collision Cross Section211.2 Ų [M-H]-

Physikochemische Eigenschaften

Schmelzpunkt
263 · 263-265C
Siedepunkt
813.2 · 813.2±65.0 °C(Predicted)
Dichte
420 · d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441
Brechungsindex
20 · nD20 1.3828; nD20 1.4327; nD20 1.4660
storage temp.
-20 °C · -20°C Freezer
Löslichkeit
DMSO (Slightly), Methanol (Slightly)
pka
11.36 · 11.36±0.46(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
InChI
InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
InChIKey
NJKDOADNQSYQEV-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)C)=C(I)C(C(NCC(O)CO)=O)=C1I
CAS Datenbank
78649 · 78649-41-9(CAS DataBase Reference)
EPA chemische Informationen
1 · 1,3-Benzenedicarboxamide, N1,N3-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)methylamino]-2,4,6-triiodo- (78649-41-9)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

hs_code
2924299090
Toxizität
LD50 (400 mgI/ml soln) i.v. in mice, rats (gI/kg): 19.9, 14.5; LD50 (370 mgI/ml soln) i.v. in dogs (gI/kg): >12.5 (Morisetti)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

V08AB10

V - Various

QV - Various

Protein BindingIomeprol does not bind to plasma proteins.
Pharmacodynamics · 1 Eintrag

The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized. At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.

Mechanism of Action · 1 Eintrag

Iomeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.

Biological Half-LifeThe elimination half-life of iomeprol is 1.8 (0.33) hours.
Metabolism/MetabolitesIomeprol does not undergo significant metabolism.
FDA Pharmacological Classification · 6 Einträge

17E17JBP8L

IOMEPROL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Iomeprol is a Radiographic Contrast Agent. The mechanism of action of iomeprol is as a X-Ray Contrast Activity.

IOMEPROL INJECTION

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4 Einträge

The maximum concentration (Cmax) and area under the concentration-time curve (AUC) are doseproportional across the dose range of 250 mg iodine/kg to 1,250 mg iodine/kg body weight.

Approximately 90% of the iomeprol dose is excreted unchanged in urine within 24 hours.

The volume of distribution of iomeprol is 0.28 (0.05) L/kg. In rats, iomeprol was shown to cross the placenta and be excreted into breast milk.

The total body clearance is 0.10 (0.01) L/hr/kg.

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >1000

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

5-AMino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxaMide Tetraacetate5-Amino-2,4,6-triiodoisophthaloyl dichloride5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethyl IoMeprol5-[[2-(Acetyloxy)acetyl]amino]-2,4,6-triiodo-1,3-benzenedicarbonyl Dichloride5-AminoisophthalsureDimethylsulfatMethyljodid

Ergänzende Hinweise

DefinitionChEBI: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a glycoloyl(methyl)amino group at the 5-position.

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung